MedAware vs NarxCare (2026)
Both score a prescribing situation for risk and they are pointed at opposite risks, which is why comparing them is useful even though almost nobody buys them against each other. NarxCare scores the patient, using state prescription monitoring data to produce controlled substance risk visualisations that a prescriber or pharmacist sees at the moment of decision. MedAware scores the prescription, detecting orders that do not fit this patient through outlier detection over longitudinal clinical data, with independent Harvard led evaluation behind it. The asymmetry that matters is in the consequence of being wrong. A false positive from MedAware wastes a pharmacist's time. A false positive from a controlled substance risk score can mean a patient in pain is refused treatment, and neither the vendor nor the states deploying it publish the subgroup performance that would tell you how often that happens.
- It is derived from state prescription monitoring data rather than from the hospital's own record, so it sees prescriptions written elsewhere that no internal system would surface.
- It is already present in many prescribing workflows through the state programme rather than requiring a separate purchase, which is a different adoption path from any commercial product here.
- Scores and visualisations are designed for a rapid decision at the point of dispensing or prescribing rather than for retrospective review.
- The detection target is different and broader: prescriptions that do not fit the patient, caught through unsupervised outlier detection over longitudinal clinical data rather than through a score built on dispensing history.
- The evidence was produced mainly by investigators independent of the company, including a Harvard Medical School group, rather than by the vendor.
- Output is an alert to a prescriber or pharmacist who decides, with the system never acting on a medication, and its integrations are confirmed by named customers.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. MedAware and NarxCare are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | MedAware | NarxCare |
|---|---|---|
| Primary category | Medication Safety & Prescribing | Medication Safety & Prescribing |
| Founded | 2012 | Not recorded |
| Headquarters | Ra'anana, Israel | Louisville, Kentucky, United States |
| Website | medaware.com | bamboohealth.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards MedAware its top capability grade on AI Centrality. Set against NarxCare, MedAware grades higher on AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Its thinnest published disclosure sits on several axes, including Model Supply Chain Disclosure, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards NarxCare its top capability grade on Security Certifications and Trust Center and EHR and Interoperability Depth. Set against MedAware, NarxCare grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Its thinnest published disclosure sits on Clinical and Operational Evidence and AI Governance and Bias Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose MedAware or NarxCare?
On the axes where the AI Health Index separates them, MedAware grades higher on AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence, and NarxCare grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. NarxCare leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do MedAware and NarxCare differ most?
The widest separation the AI Health Index records between MedAware and NarxCare is on Security Certifications and Trust Center, where MedAware grades D and NarxCare grades A. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do MedAware and NarxCare grade the same?
The AI Health Index grades MedAware and NarxCare the same on several axes, including Model and Technology Transparency, FDA and Regulatory Status and AI Governance and Bias Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have MedAware and NarxCare not disclosed?
At the last review, at least one of MedAware and NarxCare published thin or absent detail on several axes, including Model Supply Chain Disclosure, Clinical and Operational Evidence and HIPAA and BAA Posture. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Risk scoring on controlled substance history carries a consequence that exists nowhere else in this category: a false positive is not wasted time, it is a patient refused treatment. Published analyses of widely deployed prescription risk scores have found misclassification rates high enough to matter clinically, and the scored behaviours, pharmacy counts, prescriber counts and distance travelled, track access to care at least as well as they track risk, so a patient who is poor, rural or has moved will score higher for reasons unrelated to misuse. Neither vendor publishes subgroup performance or a bias assessment, and neither publishes pricing. MedAware publishes no located security attestation or business associate terms.